Table 5 Incidence of adverse events occurring in ≥ 2% of sarolaner-treated dogs presented as veterinary patients following once a month dosing with sarolaner or spinosad for three months
Adverse events | Northern study | Southern study | ||
|---|---|---|---|---|
Sarolaner (2–4 mg/kg) | Spinosad (≥ 30 mg/kg) | Sarolaner (2–4 mg/kg) | Spinosad (≥ 30 mg/kg) | |
(n = 55) | (n = 25) | (n = 50) | (n = 32) | |
Skin conditions | 6 (11%) | 5 (20%) | 11 (22%) | 13 (41%) |
Gastrointestinal conditions | 5 (9%) | 4 (16%) | 4 (8%) | 3 (9%) |
Eye conditions | 1 (2%) | 0 (0%) | 5 (10%) | 4 (13%) |
Ear conditions | 0 (0%) | 0 (0%) | 6 (12%) | 3 (9%) |
Systemic conditions | 6 (11%) | 2 (8%) | 2 (4%) | 1 (3%) |
Musculo-skeletal conditions | 2 (4%) | 1 (4%) | 0 (0%) | 2 (6%) |
Any adverse event | 14 (25%) | 10 (40%) | 21 (42%) | 20 (63%) |